ArticleThe Lancet. Oncology2022

Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy.

David Bomze et al.PubMed ↗Publisher ↗

No numbers read from the abstract.